SM 17
Alternative Names: SM-17Latest Information Update: 23 Nov 2023
At a glance
- Originator Sinomab
- Class Anti-inflammatories; Antiasthmatics; Antibodies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 17 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Asthma; Atopic dermatitis
- Preclinical Idiopathic pulmonary fibrosis
Most Recent Events
- 22 Nov 2023 Phase-I clinical trials in Asthma in China (IV) before November 2023 (SinoMab Bioscience pipeline, November 2023)
- 22 Nov 2023 Phase-I clinical trials in Atopic dermatitis in USA, China (IV) prior to November 2023 (SinoMab Bioscience pipeline, November 2023)
- 22 Nov 2023 Preclinical trials in Idiopathic pulmonary fibrosis in USA (IV) prior to November 2023 (SinoMab Bioscience pipeline, November 2023)